Lundbeck to measure brain with microscopic camera in new partnership

In a research collaboration with the US-based Inscopix, Lundbeck hopes to find some answers to the question of why it's so difficult to develop drugs against psychiatric disorders.

The US Food & Drug Administration's recent approval of Biogen's Alzheimer drug, Aduhelm, has sparked debate and controversy over how to measure the efficacy of medications against psychiatric and neurological disorders.

Lundbeck is acutely aware of this. The pharmaceutical company has previously experienced many setbacks in mid and late phase trials after preclininical and early clinical trials showed promising results.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs